摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-3H-isoindol-1-one | 133737-32-3

中文名称
——
中文别名
——
英文名称
2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-3H-isoindol-1-one
英文别名
Pagoclone
2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-3H-isoindol-1-one化学式
CAS
133737-32-3
化学式
C23H22ClN3O2
mdl
MFCD00864700
分子量
407.9
InChiKey
HIUPRQPBWVEQJJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    582.1±50.0 °C(Predicted)
  • 密度:
    1.273±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.6
  • 重原子数:
    29
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.304
  • 拓扑面积:
    63.2
  • 氢给体数:
    0
  • 氢受体数:
    4

SDS

SDS:6f060bc8ce2643b3635b10269f5737b6
查看

制备方法与用途

帕戈隆是一种特异性的γ-氨基丁酸(GABA)受体调节药物,主要用于减轻口吃症状。它是一种新型的环吡咯酮类化合物,部分地激活了GABA(A)受体。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-3H-isoindol-1-one麻黄素 、 potassium hydroxide 作用下, 以 四氢呋喃乙二醇二甲醚乙醇 为溶剂, 反应 30.25h, 生成 2-[(1S)-1-[(7-chloro-1,8-naphthyridin-2-yl)amino]-6-methyl-3-oxoheptyl]benzoic acid
    参考文献:
    名称:
    An Efficient and Cost-Effective Synthesis of Pagoclone
    摘要:
    The compound (+)-2-(7-chloro-1,8-naphthyridin-2-yl)-3S-(5-methyl-2-oxohexyl)-1-isoindolinone (pagoclone) shows anxiolytic activity due to partial agonism of the benzodiazepine site of the GABA(A) receptor. We describe the development of an economical and practical process for a 100+ kg pilot plant production used to supply development needs. For the key reaction, a beta-keto phosphonium salt was prepared by selectively reacting a primary alpha-bromo ketone with triphenylphosphine in the presence of a secondary alpha-bromo ketone. A novel Wittig reaction with a 1-isoindolinone was used to produce racemic pagoclone. The enantiomerically pure drug substance was prepared by hydrolyzing a gamma-lactam and resolving the resulting enantiomeric carboxylic acids with (+)-ephedrine hemihydrate. An alternate resolution, involving chiral multicolumn chromatography (MCC) was also developed. The synthesis was completed by a racemization-free lactam formation to afford pagoclone.
    DOI:
    10.1021/op034060b
  • 作为产物:
    参考文献:
    名称:
    An Efficient and Cost-Effective Synthesis of Pagoclone
    摘要:
    The compound (+)-2-(7-chloro-1,8-naphthyridin-2-yl)-3S-(5-methyl-2-oxohexyl)-1-isoindolinone (pagoclone) shows anxiolytic activity due to partial agonism of the benzodiazepine site of the GABA(A) receptor. We describe the development of an economical and practical process for a 100+ kg pilot plant production used to supply development needs. For the key reaction, a beta-keto phosphonium salt was prepared by selectively reacting a primary alpha-bromo ketone with triphenylphosphine in the presence of a secondary alpha-bromo ketone. A novel Wittig reaction with a 1-isoindolinone was used to produce racemic pagoclone. The enantiomerically pure drug substance was prepared by hydrolyzing a gamma-lactam and resolving the resulting enantiomeric carboxylic acids with (+)-ephedrine hemihydrate. An alternate resolution, involving chiral multicolumn chromatography (MCC) was also developed. The synthesis was completed by a racemization-free lactam formation to afford pagoclone.
    DOI:
    10.1021/op034060b
  • 作为试剂:
    描述:
    2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-3H-isoindol-1-one乙二醇二甲醚四氢呋喃氢氧化钾四氢呋喃2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-3H-isoindol-1-one二氯甲烷 作用下, 以 为溶剂, 反应 34.0h, 以to afford 150 kg (85%) of racemic-2-[1-(7-chloro-1,8-naphthyridin-2-ylamino)-6-methyl-3-oxo-heptyl ]-benzoic acid as a white solid的产率得到(±)-2-[1-(7-chloro-1,8-naphthyridin-2-ylamino)-6-methyl-3-oxoheptyl]benzoic acid
    参考文献:
    名称:
    Method for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone)
    摘要:
    本发明涉及制备外消旋2-(7-氯-1,8-萘啶基)-3-(5-甲基-2-氧代己基)-1-异吲哚酮和(+)2-(7-氯-1,8-萘啶基)-3-(5-甲基-2-氧代己基)-1-异吲哚酮的方法。
    公开号:
    US20060194830A1
点击查看最新优质反应信息

文献信息

  • [EN] IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS IMIDAZOPYRIDINE ET LEURS UTILISATIONS
    申请人:NEOMED INST
    公开号:WO2014117274A1
    公开(公告)日:2014-08-07
    This invention generally relates to substituted imidazopyridine compounds, particularly substituted 4-(imidazo[1,2-a]pyridin-2-yl)benzamide compounds and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processes for making such a compound, and intermediates used in such processes.
    这项发明通常涉及取代咪唑吡啶化合物,特别是取代的4-(咪唑[1,2-a]吡啶-2-基)苯甲酰胺化合物及其盐。这项发明还涉及包含这种化合物的药物组合物和试剂盒,以及这种化合物的用途(包括治疗方法和药物制剂等),制备这种化合物的方法,以及用于这些方法的中间体。
  • [EN] QUATERNARY PIPERIDINE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS QUATERNAIRES DE PIPÉRIDINE ET LEURS UTILISATIONS
    申请人:ASTRAZENECA AB
    公开号:WO2010071575A1
    公开(公告)日:2010-06-24
    This invention generally relates to quaternary piperidine compounds, particularly substituted 3-phenylpiperidine compounds and salts thereof. This invention also relates to pharmaceutical compositions comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), and processes for making such a compound.
    这项发明通常涉及四元哌啶化合物,特别是取代的3-苯基哌啶化合物及其盐。这项发明还涉及包括这种化合物的药物组合物、这种化合物的用途(包括治疗方法和药物制剂等),以及制备这种化合物的方法。
  • Cu/Fe Catalyzed Intermolecular Oxidative Amination of Benzylic C−H Bonds
    作者:Cong Liu、Qi Zhang、Hongbo Li、Shuangxi Guo、Bin Xiao、Wei Deng、Lei Liu、Wei He
    DOI:10.1002/chem.201600107
    日期:2016.4.25
    We report a Cu/Fe co‐catalyzed Ritter‐type C−H activation/amination reaction that allows efficient and selective intermolecular functionalization of benzylic C−H bonds. This new reaction is featured by simple reaction conditions, readily available reagents and general substrate scope, allowing facile synthesis of biologically interesting nitrogen containing heterocycles. The Cu and Fe salts were found
    我们报告了一种铜/铁共催化的Ritter型CH活化/胺化反应,该反应可实现苄基CH键的高效和选择性分子间官能化。该新反应的特征在于简单的反应条件,容易获得的试剂和一般的底物范围,从而可以轻松合成生物学上令人感兴趣的含氮杂环。发现铜盐和铁盐在这种协同催化中起不同的作用。
  • INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
    申请人:Tatani Kazuya
    公开号:US20120129890A1
    公开(公告)日:2012-05-24
    A compound (I) of the present invention, which has an EP 1 receptor antagonism: [wherein A represents a benzene ring or the like; Y 1 represents a C 1-6 alkylene group; Y 2 represents a single bond or the like; R 1 represents a hydrogen atom, a C 1-6 alkyl group or the like; R 2 represents a phenyl group which may have a substituent, a 5-membered aromatic heterocyclic ring which may have a substituent, a 6-membered aromatic heterocyclic ring which may have a substituent or the like; R 3 represents a halogen atom, a C 1-6 alkoxy group or the like; R 4 represents a hydrogen atom or the like; and R 5 represents a hydrogen atom or the like] or a pharmaceutically acceptable salt thereof is provided. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.
    本发明提供了一种具有EP1受体拮抗作用的化合物(I)[其中A代表苯环或类似结构;Y1代表C1-6烷基亚基;Y2代表单键或类似结构;R1代表氢原子、C1-6烷基团或类似结构;R2代表可能含有取代基的苯基、可能含有取代基的5元芳香杂环、可能含有取代基的6元芳香杂环或类似结构;R3代表卤素原子、C1-6烷氧基团或类似结构;R4代表氢原子或类似结构;R5代表氢原子或类似结构]或其药物可接受的盐。此外,本发明的化合物(I)可用作治疗或预防LUTS的药物,特别是OAB的各种症状。
  • Spirocyclobutyl Piperidine Derivatives
    申请人:Bernstein Peter
    公开号:US20100130477A1
    公开(公告)日:2010-05-27
    Disclosed herein is at least one spirocyclobutyl piperidine derivative, at least one pharmaceutical composition comprising at least one spirocyclobutyl piperidine derivative disclosed herein, and at least one method of using at least one spirocyclobutyl piperidine derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.
    披露至少一种螺环环丁基哌啶衍生物,至少一种包含本文披露的至少一种螺环环丁基哌啶衍生物的药物组合物,以及至少一种使用本文披露的至少一种螺环环丁基哌啶衍生物治疗至少一种组胺H3受体相关状况的方法。
查看更多